| Summary: | INTRODUCTION[|]The aim of this study was to determine the frequency of metabolic syndrome (MetS) in patients with schizophrenia and bipolar disorder (BD) receiving antipsychotic (AP) medications.[¤]METHODS[|]A total of 207 patients with schizophrenia and BD, diagnosed according to the DSM-IV criteria and receiving a regular AP treatment, were followed up in the Community Mental Health Center. The MetS was diagnosed according to the diagnostic criteria of the International Diabetes Federation. Patients with MetS were compared to those without it in terms of sociodemographic and clinical characteristics, as well as the AP medications administered.[¤]RESULTS[|]MetS was detected in 28.5% of patients. The most commonly identified clinical finding was a large waist circumference (61%). Of the clinical characteristics among the patients using AP, a large waist circumference and high blood glucose levels were found to be significantly different. MetS was found to be more common in patients with schizophrenia on AP who used the clozapine monotherapy (18.6%), and in patients with BD who used quetiapine (11.9%). Valproate was found to be more commonly used in patients with BD in whom MetS was detected.[¤]DISCUSSION AND CONCLUSION[|]A large waist circumference and high blood glucose levels are the most important follow-up criteria.[¤]
|
|---|
